A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
Clinical trial NCT04757779 · UNKNOWN
Trial details
- NCT number
- NCT04757779
- Sponsor
- First People's Hospital of Hangzhou
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-30
- Primary completion
- 2022-12-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.